Novo Nordisk unveiled Phase 1/2 trial results for amycretin, an amylin-targeting obesity drug, showing substantial weight reduction across doses but with overlapping efficacy curves. The study published in The Lancet showed patients on the highest 60 mg dose lost 24.3% body weight by 36 weeks versus 1.1% on placebo. However, similar weight-loss trends across lower doses challenge conventional dose-response expectations, prompting questions regarding optimal dosing strategies and safety profile management as the drug advances towards market evaluation.